NCT01602601View on ClinicalTrials.gov

A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Drug to GSK2788723

CompletedOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

April 9, 2012

Primary Completion Date

June 11, 2012

Study Completion Date

June 11, 2012

Conditions
Mucopolysaccharidosis II
Interventions
DRUG

Idursulfase

recombinant version of IDS produced from human fibroblast. idursulfase is approved for every week (EW) intravenous (IV) administration.

DRUG

GSK2788723

GSK2788723 is being developed by JCR and GSK for the treatment of Hunter syndrome

Trial Locations (1)

157-8535

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01602601 - A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Drug to GSK2788723 | Biotech Hunter | Biotech Hunter